Patents by Inventor Kenneth R. Shroyer
Kenneth R. Shroyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230204583Abstract: The current disclosure provides methods for detecting and analyzing KRT4 and KRT17 expression in a sample obtained from a test subject. The current disclosure pertains to methods and kits for identifying a mammalian subject with cervical cancer or non-cancerous lesions of the cervix. The current disclosure further provides methods and kits for determining the likelihood of survival or treatment outcome of a subject having cervical cancer by determining the expression level of KRT17 in a sample.Type: ApplicationFiled: November 22, 2022Publication date: June 29, 2023Applicant: The Research Foundation for The State University of New YorkInventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Emily I. Chen
-
Publication number: 20220412977Abstract: The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.Type: ApplicationFiled: May 27, 2022Publication date: December 29, 2022Applicants: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, KDX DIAGNOSTICS, INC.Inventors: Kenneth R. SHROYER, Luisa F. ESCOBAR-HOYOS, Nam KIM
-
Patent number: 11360092Abstract: The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.Type: GrantFiled: August 4, 2017Date of Patent: June 14, 2022Assignees: The Research Foundation for The State University of New York, KDx Diagnostics, Inc.Inventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Nam Kim
-
Patent number: 11092603Abstract: The instant application relates to methods for determining pancreatic cancer patient outcome and directing treatment to subjects with pancreatic cancer. The present disclosure further provides methods for measuring expression levels of cytokeratin 17 in a subject having pancreatic cancer, such as pancreatic ductal adenocarcinoma, in order to determine the subject's survival rate and clinical outcome.Type: GrantFiled: October 27, 2016Date of Patent: August 17, 2021Assignee: The Research Foundation for The State University of New YorkInventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos
-
Publication number: 20200284794Abstract: The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.Type: ApplicationFiled: August 4, 2017Publication date: September 10, 2020Applicants: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, KDX DIAGNOSTICS, INC.Inventors: Kenneth R. SHROYER, Luisa F. ESCOBAR-HOYOS, Nam KIM
-
Publication number: 20180340935Abstract: The instant application relates to methods for determining pancreatic cancer patient outcome and directing treatment to subjects with pancreatic cancer. The present disclosure further provides methods for measuring expression levels of cytokeratin 17 in a subject having pancreatic cancer, such as pancreatic ductal adenocarcinoma, in order to determine the subject's survival rate and clinical outcome.Type: ApplicationFiled: October 27, 2016Publication date: November 29, 2018Applicant: The Research Foundation for The State University of New YorkInventors: Kenneth R. SHROYER, Luisa F. ESCOBAR-HOYOS
-
Publication number: 20180059112Abstract: The current disclosure provides methods for detecting and analyzing KRT4 and KRT17 expression in a sample obtained from a test subject. The current disclosure pertains to methods and kits for identifying a mammalian subject with cervical cancer or non-cancerous lesions of the cervix. The current disclosure further provides methods and kits for determining the likelihood of survival or treatment outcome of a subject having cervical cancer by determining the expression level of KRT17 in a sample.Type: ApplicationFiled: November 6, 2017Publication date: March 1, 2018Applicant: The Research Foundation for The State University of New YorkInventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Emily I. Chen
-
Publication number: 20160187341Abstract: The current disclosure provides methods for detecting and analyzing KRT4 and KRT17 expression in a sample obtained from a test subject. The current disclosure pertains to methods and kits for identifying a mammalian subject with cervical cancer or non-cancerous lesions of the cervix. The current disclosure further provides methods and kits for determining the likelihood of survival or treatment outcome of a subject having cervical cancer by determining the expression level of KRT17 in a sample.Type: ApplicationFiled: August 8, 2014Publication date: June 30, 2016Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Kenneth R. SHROYER, Luisa F. ESCOBAR-HOYOS, Emily I. CHEN
-
Patent number: 7964195Abstract: The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: January 9, 2006Date of Patent: June 21, 2011Assignee: Diadexus, Inc.Inventors: Jackie Papkoff, Kenneth R. Shroyer
-
Publication number: 20080199461Abstract: The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: January 9, 2006Publication date: August 21, 2008Applicant: DIADEXUS, INC.Inventors: Jackie Papkoff, Kenneth R. Shroyer
-
Patent number: 5843649Abstract: Methods of distinguishing between neoplasms and pseudoneoplastic or hyperplastic processes are disclosed. The methods comprise first contacting DNA from cells of a tissue sample from a female individual with a cytosine-methylation specific endonuclease, generating amplified fragments of a cytosine-methylation regulatable polymorphic X chromosome gene using primers that bracket a restriction site of said cytosine-methylation specific endonuclease and a polymorphic sequence in said nucleotide sequence of the gene; generating heteroduplexes between amplified fragments and heteroduplex generators which consist of 1-5 nucleotide differences from the amplified fragments; and detecting the presence of a single species of heteroduplex or two species of heteroduplexes.Type: GrantFiled: March 1, 1995Date of Patent: December 1, 1998Assignee: University of ColoradoInventors: Jay Stoerker, Kenneth R. Shroyer